Therapeutic options for the majority of patients who present with metastatic disease include chemotherapy with or without PD-1/PD-L1 axis inhibition, radiotherapy, oesophageal stenting, or a combination of these [2], with no accepted standard of care in the context of a symptomatic primary tumour. This evidence concerns the gene CD274 and metastatic neoplasm.